LONG-ACTING INTERLEUKIN-15 RECEPTOR AGONIST IN COMBINATION WITH ANOTHER PHARMACOLOGICALLY ACTIVE AGENT
The instant disclosure provides a combination treatment, composition and kit comprising (a) a long-acting IL-15 receptor agonist and (b) one or more antibodies (mAb) targeting a tumor antigen, related methods of preparation and use, for example, in the treatment of conditions responsive to therapy effective to provide, for example, sustained immune activation and/or anti-tumor activity.
1 . A method of treating a subject having cancer, the method comprising:
administering to the subject
(a) a long-acting IL-15 receptor agonist having a structure:
wherein IL-15 is an interleukin-15 moiety, n is an integer from about 150 to about 3,000, m is an integer selected from 2, 3, 4, and 5, n′ is 1, and ˜NH˜ represents an amino group of the IL-15 moiety; and
(b) a monoclonal antibody that binds specifically to a tumor antigen selected from a phosphoprotein, a transmembrane protein, a glycoprotein, a glycolipid, and a growth factor, wherein the monoclonal antibody has antibody dependent cellular cytotoxicity (ADCC) as a mechanism of action;
wherein steps (a) and (b) are carried out concurrently or sequentially and in any order.
2 . The method of claim 1 , wherein the long-acting IL-15 receptor agonist is a pharmaceutically acceptable salt.
3 . The method of claim 1 or 2 , wherein (m) in Formula (I) is 2 or 3.
4 . The method of any one of claims 1 - 3 , wherein (m) in Formula (I) is 3.
5 . The method of any one of claims 1 - 4 , wherein (n) in Formula (I) has a value of about 909.
6 . The method of any one of claims 1 - 5 , wherein the cancer is a solid cancer.
7 . The method of claim 6 , wherein the solid cancer is selected from the group consisting of breast cancer, ovarian cancer, colon cancer, colorectal cancer, gastric cancer, malignant melanoma, liver cancer, small cell lung cancer, non-small cell lung cancer, thyroid cancers, kidney cancer, cancer of the bile duct, brain cancer, cervical cancer, maxillary sinus cancer, bladder cancer, esophageal cancer, Hodgkin's disease and adrenocortical cancer, including metastatic forms of any of the foregoing.
8 . The method of any one of claims 1 - 5 , wherein the cancer is a hematological malignancy.
9 . The method of claim 8 , wherein the hematological malignancy is selected from the group consisting of multiple myeloma, non-Hodgkin lymphoma, leukemia and lymphoma.
10 . The method of any one of claims 1 - 9 , wherein step (a) is carried out prior to step (b).
11 . The method of any one of claims 1 - 9 , wherein step (b) is carried out prior to step (a).
12 . The method of any one of claims 1 - 9 , wherein step (a) and step (b) are carried out concurrently or substantially concurrently.
13 . The method of any one of claims 1 - 12 , wherein said administering is effective to stimulate NK activation to an extent greater than observed when the long-acting IL-15 receptor agonist is administered as a single agent, as measured in a suitable animal model.
14 . The method of any one of claims 1 - 13 , wherein said administering is effective to stimulate NK proliferation to an extent greater than observed when the long-acting IL-15 receptor agonist is administered as a single agent, as measured in a suitable animal model.
15 . The method of any one of claims 1 - 14 , wherein said administering is effective to support CD8+ T-cell survival and memory formation to an extent greater than observed when the long-acting IL-15 receptor agonist is administered as a single agent, as measured in a suitable animal model.
16 . The method of any one of claims 1 - 15 , wherein the long-acting IL-15 receptor agonist is administered subcutaneously.
17 . The method of any one of claims 1 - 16 , wherein the monoclonal antibody is administered intravenously.
18 . The method of any one of claims 1 - 17 , wherein the monoclonal antibody is selected from an anti-CD19 antibody, an anti-CD20 antibody, and an anti-CD38 antibody.
19 . The method of any one of claims 1 - 17 , wherein the monoclonal antibody that binds specifically to a glycoprotein is selected from an anti-SLAMF7 antibody, an anti-EpCAM antibody, an anti-gpA3 antibody 3, and an anti-FBP antibody.
20 . The method of any one of claims 1 - 17 , wherein the monoclonal antibody that binds specifically to a growth factor is selected from an anti-VEGF antibody, an anti-VEGFR antibody, and an anti-EGFR antibody.
21 . The method of any one of claims 1 - 17 , wherein the monoclonal antibody is an IgG antibody.
22 . The method of any one of claims 1 - 17 , wherein the monoclonal antibody is selected from the group consisting of daratumumab, rituximab, cetuximab and trastuzumab.
23 . A therapeutic combination for use in treating cancer, comprising
(a) a long-acting IL-15 receptor agonist having a structure:
wherein IL-15 is an interleukin-15 moiety, n is an integer from about 150 to about 3,000, m is an integer selected from 2, 3, 4, and 5, n′ is 1, and ˜NH˜ represents an amino group of the IL-15 moiety; and
(b) a monoclonal antibody that binds specifically to a tumor antigen selected from a phosphoprotein, a transmembrane protein, a glycoprotein, a glycolipid, and a growth factor, wherein the monoclonal antibody includes antibody dependent cellular cytotoxicity (ADCC) as a mechanism of action.
24 . The therapeutic combination of claim 23 , wherein the long-acting receptor agonist is a pharmaceutically acceptable salt.
25 . The therapeutic combination of claim 23 or 24 , wherein the long-acting IL-15 receptor agonist has a structure as described in any one of claims 3 , 4 , or 5 .
26 . A kit comprising the therapeutic combination of any one of claims 23 - 25 , accompanied by instructions for use, wherein the long-acting IL-15 receptor agonist and the monoclonal antibody are each contained in one or more individual unit dosage forms.
27 . Use of a long-acting receptor agonist to enhance NK-cell mediated antibody-dependent cellular toxicity when administered with an anti-tumor antibody.